These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25655233)

  • 1. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
    Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
    Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
    Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
    J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.
    Leichsenring J; Volckmar AL; Kirchner M; Kazdal D; Kriegsmann M; Stögbauer F; Bockmayr T; Klauschen F; Herth FJF; Penzel R; Warth A; Schirmacher P; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2018 Feb; 57(2):70-79. PubMed ID: 29044880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
    Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
    Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Integrative Genomic Analysis of Formalin Fixed Paraffin-Embedded Archived Serous Ovarian Carcinoma Comparing Long-term and Short-term Survivors.
    Stålberg K; Crona J; Razmara M; Taslica D; Skogseid B; Stålberg P
    Int J Gynecol Cancer; 2016 Jul; 26(6):1027-32. PubMed ID: 27177282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
    Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
    Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
    Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Fehniger JE; Berger AA; Juckett L; Elvin J; Levine DA; Zajchowski DA
    Gynecol Oncol; 2019 Dec; 155(3):473-482. PubMed ID: 31703812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".
    Schwartz M; Camacho-Vanegas O; Wood AM; Dashkoff M; Whitelock C; Harkins TT; Cohen CJ; Beddoe AM; Dottino P; Martignetti JA
    Int J Gynecol Cancer; 2018 Mar; 28(3):479-485. PubMed ID: 29324546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.